Overexpression of HSPA2 is correlated with poor prognosis in esophageal squamous cell carcinoma

Hang Zhang¹, Wei Chen¹, Chao-Jun Duan² and Chun-Fang Zhang¹*

Abstract

Background: Heat shock-related 70 kDa protein 2 (HSPA2) has been identified as a potential cancer-promoting protein expressed at abnormal levels in a subset of cancers. However, its important role in esophageal squamous cell carcinoma (ESCC) is hardly known by people. The purpose of this study is to assess HSPA2 expression and to explore its role in ESCC.

Methods: Thirty ESCC samples, paired adjacent non-cancerous tissues and normal esophageal tissues, were collected for HSPA2 detection by quantitative RT-PCR (qRT-PCR) and western blotting. Additionally, the expression of HSPA2 in ESCC and adjacent non-cancerous tissues from 120 patients was analyzed by immunohistochemistry, and correlated with clinicopathological parameters and patients’ outcome.

Results: HSPA2 mRNA and protein were overexpressed in ESCC tissues. Overexpression of HSPA2 was significantly associated with primary tumor, TNM stage, lymph node metastases and recurrence, respectively (all, \(P<0.05\)). Kaplan-Meier curves showed that elevated HSPA2 expression was associated with shorter disease-free survival and overall survival in ESCC patients. Cox multivariate regression analysis revealed that overexpression of HSPA2 was an independent prognostic factor in disease-free survival and overall survival for ESCC patients (hazard ratio was 2.115 and 2.210, respectively, \(P<0.05\)).

Conclusions: Our findings demonstrate that overexpression of HSPA2 may contribute to the malignant progression of ESCC and present a novel prognostic indicator for ESCC patients.

Keywords: HSPA2, Esophageal squamous cell carcinoma, Clinicopathology, Metastasis, Prognosis

Background

Esophageal cancer is the seventh leading cause of cancer deaths worldwide, while its highest incidence and mortality rates are found in Asia. For example, in China, the majority of esophageal cancer diagnoses are esophageal squamous cell carcinoma (ESCC), which is ranked as the eighth leading cause of death nationwide, mostly in northern China where the incidence rate can be as high as 800 cases per 100,000 people [1]. The incidence and mortality rates of ESCC have decreased over the last few decades in China. On the contrary, it is continuing its march as the fastest growing malignancy in the Western world [2]. ESCC patients have a high mortality rate and poor prognosis because of the high prevalence of invasion and metastasis. Therefore, it is important to identify and characterize the tumor-specific molecular markers involved in early stages of ESCC that may contribute to ESCC carcinogenesis for improving the survival of this disease.

Heat shock-related 70 kDa protein 2 (HSPA2, also known as HSP70-2) is a member of the HSP70 family of heat-shock proteins, mapped to 14q24.1 in one study [3] and to 14q22 in another [4]. HSPA2 was originally found specifically in primary spermatocytes and spermatids, described as a testis-specific protein that played an important role in spermatogenesis [5,6]. Aberrant expression of HSPA2 in testes induced primary spermatocytes to arrest in meiosis I and undergo apoptosis, which was leading to male infertility [6]. Now HSPA2 has attracted...
increased interest due to its possible involvement in carcinogenesis of non-testicular tissues. HSPA2 has been identified as a potential cancer-promoting protein expressed at abnormal levels in a subset of human cancers, such as breast cancer [7], cervical cancer [8], bladder urothelial cancer [9], nasopharyngeal carcinoma [10] and malignant tumors [11]. Some level of the HSPA2 gene activity was also observed in cell lines derived from several human cancers [12-14], while silencing of the HSPA2 gene in cancer cells led to growth arrest and decrease in tumorigenic potential [8,9,12,15]. A HSPA2 mutation was recognized by cytotoxic T lymphocyte (CTL) on a human renal cell carcinoma [16]. Furthermore, polymorphism in the HSPA2 gene is associated with an increase in the risk of developing type 1 diabetes [17], non-Hodgkin’s lymphoma [18], lung cancer [19], systemic lupus erythematosus (SLE) [20], rheumatoid arthritis [21] and inflammatory bowel diseases [22]. Overexpression of HSPA2 is correlated with increased cell proliferation, poor differentiation and lymph node metastases in human breast cancer, cervical cancer and bladder urothelial cancer [7-9]. The highest level of HSPA2 was also detected in cells of the basal layers of the skin, esophagus and bronchus epithelia. However, whether there is HSPA2 expression in ESCC or not, has not been reported in China and abroad so far.

Thus, in this study we used quantitative RT-PCR (qRT-PCR), western blotting and immunohistochemistry to evaluate HSPA2 expression and its correlation with the survival of ESCC patients. Consistent with these studies, we suggested that elevated HSPA2 expression was associated with poor survival of ESCC patients. Our findings provide insights that could lead to better diagnosis, prognosis and therapeutic opportunities for ESCC patients.

Methods
Patients and tissue specimens
Primary ESCC samples, paired adjacent non-cancerous tissues (from 2 to 3 cm away from the tumor margin) and normal tissues (greater than 7 cm away from the tumor margin) were obtained from 30 patients (20 males and 10 females, median age 52.73 years, range 35 to 69 years). The patients underwent esophagus resection between January 2004 and June 2007 at Xiangya Hospital. All patients had no history of previous malignancies and no history of radiotherapy or chemotherapy. Recurrence and metastasis were diagnosed by imaging evaluation, clinical examination, operation and postoperative pathological examination. In addition, the patients involved in this study did not have any other diseases which could cause infertility. The main clinical and pathological variables of the patients are recorded in Table 1. The follow-up time was 5 years for 120 patients, ranging from 5 months to 60 months.

qRT-PCR
Total RNA was isolated by Trizol extraction liquid (Invitrogen, Carlsbad, CA, USA). Total RNA (2 μg) was reverse transcribed by cDNA Reverse Transcription Kits (Invitrogen) according to the manufacturer's instructions. Primers were designed and synthesized by Sangon Biological Engineering Technology and Services (Shanghai, China). The primers for HSPA2 and β-actin were designed as follows: HSPA2 primer (196 bp), forward 5′-AAAAATCACCATCACCAT-3′, reverse 5′-CTAACCTTGGCCCCTCAGTTTCTC-3′; β-actin primer (205 bp), forward 5′-TGACGTGGACATCCGAAAT-3′, reverse 5′-CTGGAAGGTGGACAGCGGAGG-3′. qRT-PCR was performed with SYBR Green PCR Master Mix according to the manufacturer's instructions by using the CFX96 sequence detection system (Bio-Rad, Hercules, CA, USA) and accompanying analytical software. The reaction was first denatured at 95°C for 10 minutes, then 40 cycles at 95°C for 10 seconds, 60°C for 20 seconds and followed by 72°C for 10 seconds.

Western blotting
HSPA2 protein was extracted using a Total Protein Extraction Kit (Beyotime, Haimen, Jiangsu, China). Briefly, all proteins were resolved on 10% SDS-PAGE in running buffer and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). After blocking with 5% milk for 2 hours, the membranes were incubated with primary antibodies against HSPA2 (Santa Cruz Biotechnology, Dallas, TX, USA) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Beyotime) at room temperature for 2 hours. The membranes were then washed with PBS Tween 20 and incubated with secondary antibody goat anti-mouse immunoglobulin G (IgG)/horse-radish peroxidase (HRP) (1:1000, Beyotime) for 1 hour at room temperature. Enhanced chemiluminescence (ECL) detection of the target protein was performed using a Pierce ECL system (Thermo Scientific, Waltham, MA, USA). HSPA2 protein expression levels were quantified by Bio-Rad Image Lab software and presented as the densitometric ratio of the targeted protein to GAPDH.
All specimens were fixed with 4% formaldehyde, dewaxed, embedded and cut into 4 μm serial sections. Briefly, antigen retrieval was carried out in 10 mmol/l citrate buffer (pH 6.0) for 15 minutes at 100°C in a microwave oven. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10 minutes at room temperature. The sections were then incubated overnight at 4°C with anti-HSPA2 antibody (Santa Cruz Biotechnology). After washing with PBS, sections were incubated with secondary antibodies for 30 minutes at 37°C. The sections were then washed three times with PBS and treated with 3,3’-diaminobenzidine (DAB) for approximately 5 minutes. Finally, the sections were counterstained with hematoxylin, dehydrated, mounted and examined by light microscopy. Negative controls were probed with PBS under the same experimental conditions.

Immunohistochemical staining was assessed by two independent experienced pathologists who were blinded to all clinicopathological features. Five high power fields in each specimen were randomly selected, in which nuclear and/or cytoplasmic staining was considered to be positive staining for HSPA2. A staining index (values 0 to 9), obtained as a product of staining intensity (0 to 3: 0 point, no intensity; 1 point, weak intensity; 2 points, moderate intensity; 3 points, strong intensity) multiplied by the proportion of immunopositive cells of interest (≤10% = 1; 10% to 50% = 2; ≥50% = 3). Tumors were categorized into three groups according to the final staining index: negative or weak staining (scored 0 to 3), moderate staining (scored 4 to 6) and strong staining (scored 7 to 9). ESCC patients were dichotomized into a negative expression group (negative and weak staining scored 0 to 3), and positive expression group (moderate and strong staining scored 4 to 9) in order to better analyze the prognosis between groups.

**Statistical analysis**

All continuous variables were expressed as mean ± SD from at least three separate experiments. HSPA2 levels in ESCC samples, adjacent non-cancerous tissue and normal tissues were examined by Wilcoxon signed-rank test. The association between HSPA2 and clinicopathological features was analyzed using χ² test. Survival curves were obtained using Kaplan-Meier curves and log-rank tests. Multivariate prognostic factors were examined by the Cox proportional hazards model. A value of P <0.05 was considered to be statistically significant. All statistical calculations were performed with SPSS Statistics 18.0 software (IBM, Armonk, NY, USA).

**Results**

**Expression of HSPA2 in different esophageal tissues**

HSPA2 mRNA and protein expressions were detected in the 30 pairs of primary ESCC samples, adjacent non-cancerous tissues and normal tissues. The results in Figure1A show that HSPA2 mRNA levels in the ESCC

| Parameters                  | Cases | HSPA2 expression (n) | χ²   | P value |
|-----------------------------|-------|----------------------|------|---------|
| Tissues                     |       |                      |      |         |
| Cancer                      | 120   | 90                   | 30   | 21.343  | 0.000  |
| Adjacent                    | 120   | 55                   | 65   |         |        |
| Age (years)                 |       |                      |      |         |
| ≤60                         | 81    | 64                   | 17   | 2.140   | 0.144  |
| >60                         | 39    | 26                   | 13   |         |        |
| Gender                      |       |                      |      |         |
| Male                        | 90    | 69                   | 21   | 0.533   | 0.465  |
| Female                      | 30    | 21                   | 9    |         |        |
| Drinking                    |       |                      |      |         |
| Yes                         | 75    | 59                   | 16   | 1.434   | 0.231  |
| No                          | 45    | 31                   | 14   |         |        |
| Tumor site                  |       |                      |      |         |
| Upper                       | 35    | 26                   | 9    | 0.017   | 0.992  |
| Middle                      | 40    | 30                   | 10   |         |        |
| Lower                       | 45    | 34                   | 11   |         |        |
| Grade                       |       |                      |      |         |
| G1                          | 63    | 49                   | 14   | 0.672   | 0.715  |
| G2                          | 30    | 21                   | 9    |         |        |
| G3 + G4                     | 27    | 20                   | 7    |         |        |
| Primary tumor               |       |                      |      |         |
| T1                          | 30    | 18                   | 12   | 9.340   | 0.025a |
| T2                          | 31    | 21                   | 10   |         |        |
| T3                          | 42    | 35                   | 7    |         |        |
| T4                          | 17    | 16                   | 1    |         |        |
| TNM stage                   |       |                      |      |         |
| I                           | 28    | 14                   | 14   | 14.991  | 0.001a |
| II                          | 49    | 37                   | 12   |         |        |
| III                         | 43    | 39                   | 4    |         |        |
| Lymph node metastases       |       |                      |      |         |
| N0                          | 76    | 51                   | 25   | 6.890   | 0.009a |
| N+                          | 44    | 39                   | 5    |         |        |
| Recurrence                  |       |                      |      |         |
| Yes                         | 85    | 70                   | 15   | 8.497   | 0.004a |
| No                          | 32    | 18                   | 14   |         |        |

*P values considered statistically significant at <0.05; †three patients lost to follow-up because of telephone number changes or home moving. ESCC, esophageal squamous cell carcinoma; G, grade; N, lymph node metastases; T, primary tumor. Drinking alcohol is defined as average amount of drinking alcohol is 50 grams or more per day, and period of drinking continues to 1 year or more. Drinking alcohol parameter: amount of drinking/day × years of drinking.
tissues were higher than in the adjacent non-cancerous tissues (3.1742 ± 1.6866 versus 1.2440 ± 0.6702, \( P < 0.05 \)). However, no significant differences were found between adjacent non-cancerous tissues and normal tissues (\( P > 0.05 \)). We also found that HSPA2 mRNA had different expression levels in the ESCC tissues at different tumor stages. As shown in Figure 1B, HSPA2 mRNA expression in advanced-stage ESCC tissues (n = 16) at stage III was significantly higher than in early-stage ESCC tissues (n = 14) at stages I and II (\( P < 0.05 \)). Western blotting analysis showed that the HSPA2 protein expression in ESCC tissues was significantly higher than in adjacent non-cancerous tissues and normal tissues (\( P < 0.05 \)) (Figure 1C, D).

**Correlation of HSPA2 expression with clinicopathological characteristics of ESCC tissues**

A total of 120 pairs of paraffin-embedded ESCC and adjacent non-cancerous tissues were analyzed by immunohistochemistry. The positive expression rate of HSPA2 in ESCC tissues (90/120, 75%) was significantly higher than in the adjacent non-cancerous tissues (55/120, 45.83%, \( P < 0.05 \)). As shown in Figure 2, HSPA2-positive staining was predominantly observed in the nucleus and some occurred in the cytoplasm. HSPA2 are classified as cytosol/nuclear proteins able to translocate between the cytoplasm and nucleus [14]. At physiological temperature, the HSPA2 is localized primarily in cytoplasm, whereas the HSPA2 localization shifts to the nucleus and nucleoli in heat-shock cancer cells [14,23]. From immunohistochemical analysis, the clinicopathological data of the patients are summarized in Table 1. Overexpression of HSPA2 was significantly associated with primary tumor, TNM stage, lymph node metastases and recurrence respectively (all, \( P < 0.05 \)). There were no significant differences in age, gender, drinking, tumor site or tumor grade.

**Prognostic significance of HSPA2 expression in ESCC patients**

At the end of clinical follow-up, survival information was available for 117 of 120 patients; three patients were lost to follow-up because of telephone number changes or home moving. Patients were divided into a HSPA2-positive group (n = 90) and a HSPA2-negative group (n = 30). Kaplan-Meier curves of survival analysis demonstrated that patients with HSPA2-positive expression had a shorter overall survival than patients with HSPA2-negative expression (survival rate: 18.9% versus 66.7%, \( P < 0.001 \)) (Figure 3). Analysis of disease-free survival also obtained a similar
result (survival rate: 7.8% versus 40%, \( P < 0.001 \)). As shown in Table 2, univariate analysis showed that overall survival and disease-free survival were correlated with primary tumor, TNM stage, lymph node metastases and HSPA2 expression. Furthermore, Cox multivariate regression analysis indicated that HSPA2 expression, primary tumor and TNM stage were considered as independent prognostic factors for overall survival and disease-free survival in Table 3.

Discussion

The HSPA2 gene was originally characterized as a counterpart of the testis-specific rodent HST70/HSP70-2 gene, which was specially and highly expressed in the testis [5,6]. Recently, research has shown that human tumor cells and some somatic tissues can express this gene at significant levels [7-10,12-14]. The polymorphism of HSPA2 at position 1267 has been suggested to be associated with carcinogenesis in many malignant cancer tissues [7-10].
The highest level of HSPA2 is also detected in cells of the basal layers of the esophagus [23], but the function of HSPA2 in basal cells, which may be involved in the proliferation and/or differentiation of epidermal keratinocytes, is currently unknown.

In this study, the expression levels of HSPA2 mRNA and protein in the ESCC tissues were significantly higher than in adjacent non-cancerous tissues and normal esophageal tissues, consistent with other cancer reports [7-9]. As a chaperone protein, HSPA2 is essential for the growth of spermatocytes and cancer cells, and it is known to be involved in apoptosis and regulation of cell proliferation [18]. Silencing the expression of the HSPA2 gene by RNA interference suggests that HSPA2 increases the growth rate and tumorigenic potential not only in the cell culture but also in tumor xenograft in mice [7-9,15]. However, the underlying mechanisms for the high expression of HSPA2 in tumors remain incompletely understood, but likely involve regulatory processes, such as cell cycling. Indeed, HSPA2 appears to be a molecular chaperone for CDC2 and is required for CDC2/cyclinB1 complex formation, whose destruction can prevent development of the CDC2 kinase activity, required to trigger G2/M phase transition [24]. During meiosis, spermatogenic cells synthesize HSPA2, knock-out of HSPA2 in HSPA2 (−/−) male mice testes induce primary spermatocytes to arrest in meiosis I and undergo a dramatic increase in spermatocyte apoptosis, which was leading to male infertility [6]. HSPA2 overexpression protects V79 fibroblasts against bortezomib-induced apoptosis [25]. The mechanism of a mutated HSPA2 chaperone has a dominant effect in tumor cells by triggering the G2/M phase transition during the mitotic cell cycle, which could explain the HSPA2 abnormal expression in somatic tumors. Moreover, downregulation of lens epithelium-derived growth factor (LEDGF) is responsible for the death of HSPA2-depleted cancer cells and LEDGF possesses great oncogenic potential [26]. HSPA2 may also have a potential role in cancer pathogenesis by participating in the regulation of antitumor immunity, such as acting as a chaperone molecule for immunogenic tumor-associated peptides [27], while HSPA2 has been identified as a putative susceptibility locus in organ-specific autoimmune diseases. Lastly, a new regulatory mechanism of HSPA2 expression in tumor cells has been disclosed, which suggests that the upregulation of HSPA2 enhanced the resistance of tumor cells to hypoxia-induced apoptosis, which provides a new insight into how tumor cells overcome hypoxic stress and survive [28].

Immunohistochemical analysis of a large set of specimens revealed that HSPA2 protein was positively expressed in 75% (90/120) ESCC tissues, compared to

Table 2 Univariate survival analysis of overall survival and disease-free survival in 120 patients with ESCC

| Features                    | Overall survival | Disease-free survival |
|-----------------------------|------------------|-----------------------|
|                             | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
| Age (≤60/>60 years)          | 0.713 (0.456 to 1.116) | 0.139 | 0.745 (0.493 to 1.125) | 0.162 |
| Gender (female/male)         | 0.915 (0.553 to 1.513) | 0.728 | 0.975 (0.624 to 1.525) | 0.913 |
| Drinking (yes/no)            | 1.043 (0.670 to 1.622) | 0.853 | 1.017 (0.681 to 1.518) | 0.935 |
| Tumor site (upper + lower/middle) | 1.347 (0.797 to 2.277) | 0.266 | 1.216 (0.768 to 1.926) | 0.405 |
| Grade (G2 + G3 + G4/G1)      | 1.347 (0.797 to 2.277) | 0.266 | 1.216 (0.768 to 1.926) | 0.405 |
| Lymph node metastases (−/+ ) | 2.157 (1.380 to 3.372) | 0.001a | 1.872 (1.256 to 2.791) | 0.002a |
| TNM stage (III/I + II)       | 21.177 (11.057 to 40.561) | <0.001a | 15.085 (8.320 to 27.350) | <0.001a |
| Lymph node metastases (−/+ ) | 0.572 (0.369 to 0.887) | 0.026a | 0.625 (0.418 to 0.935) | 0.022a |
| HSPA2 expression (positive/negative) | 3.557 (1.827 to 6.922) | 0.001a | 2.901 (1.721 to 4.888) | 0.001a |

*P values considered statistically significant at <0.05. CI, confidence interval; ESCC, esophageal squamous cell carcinoma; G, grade; N, lymph node metastases; T, primary tumor.

Table 3 Multivariate survival analysis of overall survival and disease-free survival in 120 patients with ESCC

| Features                    | Overall survival | Disease-free survival |
|-----------------------------|------------------|-----------------------|
|                             | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
| Primary tumor (T3 + T4/T1 + T2) | 1.746 (1.104 to 2.762) | 0.017a | 1.516 (1.005 to 2.289) | 0.048a |
| TNM stage (III/I + II)       | 16.347 (8.560 to 31.215) | <0.001a | 11.729 (6.448 to 21.335) | <0.001a |
| Lymph node metastases (−/+ ) | 0.838 (0.534 to 1.315) | 0.442 | 0.906 (0.596 to 1.375) | 0.642 |
| HSPA2 expression (positive/negative) | 2.210 (1.101 to 4.435) | 0.026a | 2.115 (1.222 to 3.661) | 0.007a |

*P values considered statistically significant at <0.05. CI, confidence interval; ESCC, esophageal squamous cell carcinoma; G, grade; N, lymph node metastases; T, primary tumor.
45.83% (55/120) in adjacent non-cancerous tissues ($P < 0.05$). We correlated HSPA2 protein expression with various clinicopathological factors in 120 ESCC patients. Our results showed that overexpression of HSPA2 was significantly associated with primary tumor, TNM stage, lymph node metastases and recurrence respectively (all, $P < 0.05$). We also found HSPA2 mRNA expression in advanced-stage ESCC tissues at stage III was significantly higher than in early-stage ESCC tissues at stages I and II. These data revealed a potential association between HSPA2 overexpression and malignant phenotypes, such as metastasis, consistent with other reports in breast cancer [7], cervical cancer [8] and bladder urothelial carcinoma [9]. It is well known that the HSPA2 is localized primarily in cytoplasm at physiological temperature, whereas HSPA2 migrates to the nucleus and nucleoli under heat-shock conditions [14,23], and our results confirm this theory. The phenomenon of HSPA2 translocation into the nucleus and nucleoli has been presently found in many other heat-shock cancer cells, which is part of a cellular protective response under stress conditions, but the mechanism is currently unknown. Generally, HSPA2 is involved in intracellular trafficking and nuclear receptor binding, which also prevents inappropriate protein aggregation and mediates transport of immature (or damaged) proteins to target subcellular compartments for final packaging, degradation or repair [29]. Since HSPA2 shuttles continuously between the cytoplasm and nucleus during heat-shock, this cell migration is critical for tumor formation and metastasis.

It is widely accepted that metastasis contributes to the high mortality rate for patients with ESCC. Our data revealed that high HSPA2 protein expression was well correlated with lymph node metastasis and predicted worse prognosis. Although close association between HSPA2 expression and ESCC metastasis has been established in our study, the possible mechanisms are still unclear and need further investigation. Moreover, lymph node metastasis is one of the vital elements of TNM stage. It is also well known that lymph node metastasis frequently occurs in advanced-stage ESCC patients. Therefore, it is not difficult to explain the reason for overexpression of the HSPA2 gene in late stages. The abnormal excessive proliferation of tumor cells also frequently occurs in late stages and overexpression of HSPA2 can promote development of the CDC2 kinase activity, required to trigger G2/M phase transition and regulate cell proliferation through controlling cell cycling. The overexpression of HSPA2 leads to the prolonged cell cycling arrest at the G2 phase. Most importantly, the resistance of tumor cells to hypoxia-induced apoptosis in late stages is very strong and the new regulatory mechanism mentioned above indicates that the upregulation of HSPA2 may enhance the resistance of tumor cells to hypoxia-induced apoptosis. All these theories illustrate that overexpression of HSPA2 promotes the occurrence and development of ESCC.

Finally, patients with HSPA2-positive expression were significantly associated with shorter disease-free and overall survival by using the Kaplan-Meier analysis. Therefore, HSPA2 protein expression pattern might be a valuable prognostic marker for ESCC patients. More importantly, from univariate and multivariate analysis, we obtained sufficient evidence to deduce that HSPA2 expression level was an independent prognostic indicator for patients with ESCC. Overexpression of HSPA2 is correlated with poor therapeutic outcomes in human breast cancer, cervical cancer and bladder urothelial cancer; furthermore, it is now a valuable prognostic marker for breast cancer patients [7]. The polymorphism of HSPA2 acts as an attractive susceptibility marker and independent prognostic indicator in Kangri cancer patients [30]. Considering the frequency of positivity of HSPA2 in adjacent non-cancerous tissues is much higher, whether or not HSPA2 molecule can be qualified to be a prognostic biomarker will need to be validated in future clinical work.

**Conclusions**

Our present study demonstrated that elevated HSPA2 expression levels was positively associated with the progression and poor prognosis in patients with ESCC, which indicated that HSPA2 might serve as a valuable prognosis marker for ESCC patients. However, the possible underlying mechanisms for its participation in ESCC progression are still unclear. Therefore, the next step we will take will be further research of the cell signaling pathway in order to gain a better molecular mechanism understanding in this field.

**Abbreviations**

CI: Confidence interval; CTL: Cytotoxic T lymphocyte; DAB: 3,3′-diaminobenzidine; ECL: Enhanced chemiluminescent; ESCC: Esophageal squamous cell carcinoma; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; HRP: Horseradish peroxidase; HSPA2: Heat shock-related 70 kDa protein 2; IgG: Immunoglobulin G; LEDGF: Lens epithelium-derived growth factor; PBS: Phosphate buffered saline; qRT-PCR: Quantitative RT-PCR; RT-PCR: Reverse transcription polymerase chain reaction; SLE: Systemic lupus erythematosus.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

ZH carried out the qRT-PCR and western blotting, participated in the sequence alignment and drafted the manuscript. CW carried out the immunohistochemistry. DCJ participated in the design of the study and performed the statistical analysis. ZCF conceived of the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.
Acknowledgments

We thank Liyuan Feng (Department of Pathology, Xiangya Hospital, Central South University, China) and Xueping Feng (Central Laboratory of Medical Research, Xiangya Hospital, Central South University, China) for their evaluation of these clinical samples.

Financial support

This work was supported by grants from the National Natural Scientific Foundation of Hunan, China (number 2010FJ3134). This work was supported by grants from the National Natural Scientific Foundation of Hunan, China (number 2010FJ3134). This work was supported by grants from the National Natural Scientific Foundation of Hunan, China (number 2010FJ3134).

Author details

1. Department of Cardiothoracic Surgery, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha, Hunan Province 410008, People’s Republic of China. 2. Medical Science Institute, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha, Hunan Province 410008, People’s Republic of China.

Received: 5 March 2013 Accepted: 2 June 2013

References

1. Chai J, Jamal MM: Esophageal malignancy: A growing concern. World J Gastroenterol 2012, 18:6521–6526.
2. Köhler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajiya UA, Edwards BK: Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011, 103:714–736.
3. Bonnycastle LL, Yu CE, Hunt CR, Taski BJ, Dancy KP, Weber JL, Patterson D, Schellenberg GD: Cloning, sequencing, and mapping of the human chromosome 14 heat shock protein gene (HSPA2). Genomics 1994, 23:85–93.
4. Roux AF, Nguyen VT, Squire JA, Cox DW: A heat shock gene at 14q22: mapping and expression. Hum Mol Genet 1994, 3:1819–1822.
5. Dix DJ, Allen JW, Collins BW, Poorman-Allen P, Mori C, Blizzard DR, Brown PR, Goulding EH, Strong BD, Eddy EM: HSP70-2 is required for desynthesis of synaptosomal complexes during meiotic prophase in juvenile and adult mouse spermatocytes. Development 1997, 124:4595–4603.
6. Dix DJ, Allen JW, Collins BW, Mori C, Nakamura N, Poorman-Allen P, Goulding EH, Eddy EM: Targeted gene disruption of Hsp70-2 results in failed meiosis, germ cell apoptosis, and male infertility. ProchlastAcadSci U S A 1996, 93:3264–3268.
7. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Chouchane L: Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 2001, 91:672–678.
8. Garg M, Kanodia D, Saini S, Suri A, Gupta A, Suraliya A, Suri A: Germ cell-specific heat shock protein 70-2 is expressed in cervical carcinoma and is involved in the growth, migration, and invasion of cervical cells. Cancer 2010, 116:3785–3796.
9. Garg M, Kanodia D, Seth A, Kumar R, Gupta A, Suraliya A, Suri A: Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur J Cancer 2010, 46:207–215.
10. Jallout M, Bouaouina N, Garjouri J, Corbeix M, Ben Ahmed S, Chouchane L: Polymorphism of the stress protein HSP70-2 gene is associated with the susceptibility to the nasopharyngeal carcinoma. Cancer Lett 2003, 193:75–81.
11. Chouchane L, Ahmed SB, Baccouche S, Remadi S: Polymorphism in the tumor necrosis factor-alpha promoter region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997, 80:1489–1496.
12. Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jaattela M: Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 2005, 19:570–582.
13. Piglowski W, Nowak R, Krawczyk Z, Scieglinska D: The structural and functional analysis of the human HSPA2 gene promoter region. Acta Biochim Pol 2007, 54:99–108.
14. Scieglinska D, Piglowski W, Mazurek A, Malusiec E, Zebracka J, Filipczak P, Krawczyk Z: The HSPA2 protein localizes in nucleoli and centromeres of heat shocked cancer cells. J Cell Biochem 2008, 104:2193–2206.
15. Xia LM, Tian DA, Zhang Q, Yan W, Wang B, Liu M, Li PY, B C: Inhibition of HSP70-2 expression by RNA interference induces apoptosis of human hepatocellular carcinoma cells. Zhonghua Gan Zang Bing ZaZhi 2008, 16:678–682.
16. Gaudin C, Kremer F, Angoev E, Scott V, Triebel F: A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999, 162:1730–1738.
17. Pocett F, Ronningen KS, Nerup J: Polymorphic analysis of the human MHC-linked heat shock protein 70 (HSP70-2) and HSP70-Hom genes in insulin-dependent diabetes mellitus (IDDM). Scand J Immunol 1993, 38:491–495.
18. Daugaard M, Jaattela M, Rohde M: Hsp70-2 is required for tumor cell growth and survival. Cell Cycle 2005, 4:877–880.
19. Wang Y, Zhou P, Wu Y, Xu D, Li W, Liang S: The relationship between three heat shock protein 70 gene polymorphisms and susceptibility to lung cancer. Chin Med Lab Med 2010, 48:1657–1663.
20. Pablos JJ, Carreia PE, Martin-Villa JM, Montalvo G, Arnaiz-Villena A, Gomez-Reino JJ: Polymorphism of the heat-shock protein gene HSP70-2 in systemic lupus erythematosus. Br J Rheumatol 1995, 34:721–725.
21. Vinasco J, Benua Y, Nieto A, Fraile A, Pareja E, Mataran L, Martin J: Heat shock protein 70 gene polymorphisms in rheumatoid arthritis. Tissue Antigens 1997, 50:71–73.
22. Debler J, Schiemann U, Seybold U, Mussack T, Landauer N, Ladurner R, Gross M: Heat-shock protein HSP70-2 genotypes in patients with Crohn’s disease: a more severe clinical course with intestinal complications in presence of the PstI-polymerism. Eur J Med Res 2003, 8:120–124.
23. Scieglinska D, Piglowski W, Chekan M, Mazurek A, Krawczyk Z: Differential expression of HSPA1 and HSP2A proteins in human tissues; tissue microarray-based immunohistochemical study. Histochem Cell Biol 2011, 135:337–350.
24. Zhu D, Dix DJ, Eddy EM: HSP70-2 is required for CD2 kinase activity in meiosis I of mouse spermatocytes. Development 1997, 124:3007–3014.
25. Filipczak PT, Piglowski W, Glowala-Kosinska M, Krawczyk Z, Scieglinska D: HSPA2 overexpression protects V79 fibroblasts against bortezomib-induced apoptosis. Biochem Cell Biol 2012, 90:224–231.
26. Daugaard M, Kirkegaard-Sorensen T, Osterfeld MS, Aaboee M, Hoyer-Hansen M, Orntoft TF, Rohde M, Jaattela M: Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer. Cancer Res 2007, 67:2559–2567.
27. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E: Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2003, 101:245–252.
28. Xia LM, Tian DA, Zhang Q, Yan W, Zhu Q, Luo M, Zhou ZZ, Yang Y, Zhang QL, Wang W: Hypoxia induces heat shock protein 54 expression in a HIF-1 dependent manner. Zhonghua Gan Zang Bing ZaZhi 2008, 17:207–212.
29. Widlak W, Wydra N, Malusiec E, Dubladava W, Winianski B, Scieglinska Q, Widlak P: Heat shock transcription factor 1 down-regulates spermatoocyte-specific 70 kDa heat shock protein expression prior to the induction of apoptosis in mouse testes. Genes Cells 2007, 12:487–499.
30. Rehman SU, Sameer AS, Zahoor L, Syeed N, Nanda MS, Haifz A, Shaik ZA, Siddiqui MA: Polymorphic analysis of MHC-linked Heat Shock Protein 70 genes: Their susceptibility and prognostic implication in Kangri cancer cases of Kashmiri population. Indian J Hum Genet 2009, 15:65–71.

Cite this article as: Zhang et al.: Overexpression of HSPA2 is correlated with poor prognosis in esophageal squamous cell carcinoma. World Journal of Surgical Oncology 2013 11:141.